Sacituzumab Tirumotecan for Bladder Cancer

(TroFuse-031 Trial)

This trial tests a new medicine, sacituzumab tirumotecan (sac-TMT), to determine if it can extend the lives of people with advanced bladder cancer. Researchers compare this experimental treatment to existing chemotherapy options to identify which is more effective for those whose cancer has worsened after previous treatments. Eligible participants should have bladder cancer that has spread and continued to progress after treatments such as platinum-based chemotherapy and specific targeted therapies. As a Phase 3 trial, this study serves as the final step before potential FDA approval, providing participants access to a promising treatment option.

The trial protocol does not specify if you must stop taking your current medications. However, you cannot have received any systemic anticancer therapy within 4 weeks before starting the trial, and you should not be on chronic systemic steroid therapy or other immunosuppressive treatments within 7 days prior to the trial.

Research has shown that sacituzumab tirumotecan (sac-TMT) has generally been well-tolerated in past studies. Participants taking sac-TMT did not experience any serious treatment-related deaths, and no reports of febrile neutropenia, a dangerous drop in white blood cells with fever, were noted. This suggests the treatment might be safe for most people. Additionally, studies found that sac-TMT showed promising results in controlling advanced bladder cancer. Safety can vary, so discussing participation with a healthcare provider is important.¹²³⁴⁵

Unlike the standard of care for bladder cancer, which typically involves chemotherapy drugs like paclitaxel, docetaxel, or vinflunine, sacituzumab tirumotecan offers a novel approach by targeting a specific protein on cancer cells. This drug combines an antibody that seeks out the Trop-2 protein, often found in high levels on bladder cancer cells, with a potent chemotherapy agent, delivering treatment directly to the cancer site. Researchers are excited about sacituzumab tirumotecan because this targeted delivery method could potentially reduce side effects and improve effectiveness compared to traditional chemotherapy.

Studies have shown that sacituzumab tirumotecan (sac-TMT), which participants in this trial may receive, has promising results in treating advanced bladder cancer. Specifically, earlier research demonstrated that sac-TMT reduced tumor size in about 31% of patients. Additionally, 71% of patients experienced disease control, meaning their cancer did not worsen during treatment. These findings suggest that sac-TMT could be an effective treatment option for those whose bladder cancer has progressed after other therapies. Meanwhile, another group in this trial will receive chemotherapy, including options like paclitaxel, docetaxel, or vinflunine, to compare its effectiveness against sac-TMT.¹²⁴⁵⁶